フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
Denosumab Trial Met Primary and All Secondary Endpoints by Significantly Delaying Time to First Skeletal Related Event and Significantly Reducing...
Fourth Quarter 2009 Revenue Increased 2 Percent to $3.8 Billion; Full Year 2009 Revenue Decreased 2 Percent to $14.6 Billion Fourth Quarter 2009...
THOUSAND OAKS, Calif., Jan. 21 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) today announced that detailed results from two pivotal Phase 3...
THOUSAND OAKS, Calif., Jan. 20 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) today announced that it plans to report its fourth quarter and...
Company, Staff Contributions To Help Haitian Victims THOUSAND OAKS, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) today...
THOUSAND OAKS, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) will present at the 28th Annual JP Morgan Global Healthcare...
Roche Admits Infringement And Validity Of Amgen's EPO Patents; Court Enters Permanent Injunction; Amgen Allows Roche's MIRCERA Onto U.S. Market In...
THOUSAND OAKS, Calif., Dec. 18 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) announced today that Roger M. Perlmutter, M.D., Ph. D., Amgen's...
THOUSAND OAKS, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) today announced that its board of directors has authorized...
Applications for 2010 Amgen Scholars U.S. and Europe Programs Now Available THOUSAND OAKS, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Each year...
Nplate(R) Data Documents Long-Term Safety and Efficacy for Treatment of Serious Chronic Autoimmune Disorder THOUSAND OAKS, Calif., Nov. 30...
THOUSAND OAKS, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) was honored with two 2009 Scrip Awards, winning for Best Overall...
THOUSAND OAKS, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) will participate in the Lazard Capital Healthcare Conference on...
THOUSAND OAKS, Calif., Nov. 12 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) will participate in the 18th Annual Credit Suisse Healthcare...
Phase 3 Results Reinforce Importance of KRAS Status THOUSAND OAKS, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) today announced...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約